1. Introduction {#s0005}
===============

Similar to solid organs, T cells have been suggested to harbour a self-renewing stem cell-like population which permanently replenishes the pools of further differentiated effectors. Since central memory T (T~CM~) cells have been shown to repopulate the effector memory T (T~EM~) cell and effector T (T~EFF~) cell pools in response to antigen stimulus ([@bb0095], [@bb0195]), they were thus far regarded as "memory stem cells". However, further complexity was brought to this view by the recent discovery of an additional memory T cell subset, which was able to mediate a prolonged immune response in a mouse model of graft-*versus*-host disease (GVHD) ([@bb0210]). This memory T cell subset, termed stem cell-like memory T (T~SCM~) cells, has been recently described in mice, non-human primates and in humans ([@bb0085], [@bb0090], [@bb0120]). As least differentiated distinct memory T cell subset, T~SCM~ cells have been put at the top of the hierarchy of all memory T cell subsets in a model of progressive T cell differentiation, leading from naive T (T~N~) cells over T~SCM~ cells and T~CM~ cells to T~EM~ cells and T~EFF~ cells. This position of T~SCM~ cells between T~N~ cells and memory T cells is phenotypically reflected by the expression of activation markers as the death receptor CD95, the β-chain of the IL-2 receptor (CD122) or the adhesion molecule CD58 on naive-appearing CCR7 +, CD45RA +, CD45RO − T cells ([@bb0090]). After genetic modification into mesothelioma-specific CAR T cells, adoptively transferred T~SCM~ cells were shown to mediate an improved anti-tumour immune response compared to T~N~ cells, T~CM~ cells and T~EM~ cells in a humanized mouse model ([@bb0090]), which seems to depend on a more efficient T~SCM~ cell engraftment and long-term persistence in the host which enables them, while self-renewing, to constantly differentiate into T~EFF~ cells and, thereby, to completely eradicate the tumour.

Because of these ideal characteristics there is a quest for the signalling pathways which mediate T~SCM~ cell induction. Once identified, pharmacological interference with these signalling pathways could be used for their targeted induction in anti-tumour immunotherapy. In this regard, the *in vitro* activation of CD8 + T~N~ cells in the presence of the Wnt-β-catenin (short: Wnt) signalling pathway activator TWS119, which inhibits glycogen synthase kinase-3β (GSK-3β) by phosphorylation, has been suggested to arrest T~N~ cell differentiation and to generate T~SCM~ cells ([@bb0090]). However, the interpretability of these data remains inconclusive, since the starting pool of T~N~ cells also contained T~SCM~ cells so that an expansion effect of TWS119 on pre-existing T~SCM~ cells or T~SCM~ cell self-maintaining factors cannot be excluded. Moreover, increasing evidence suggests that T cell metabolism is an important determinant of T cell differentiation ([@bb0140]), which raises the possibility that metabolic integrators like mechanistic/mammalian Target Of Rapamycin (mTOR) kinase might represent pharmacological targets for the enrichment of a desired differentiation-defined T cell population ([@bb0010], [@bb0055], [@bb0155], [@bb0180]), thereby potentially favouring the induction of qualitatively improved memory T cells.

We, therefore, set out to investigate whether mTORC1 inhibitors like rapamycin would be relevant for the generation of human T~SCM~ cells and whether a cross-talk between mTOR and Wnt signalling would exist. Moreover, since current knowledge on the generation and characterization of T~SCM~ cells remains limited to CD8 + T~SCM~ cells, apart from their phenotypic definition, CD4 + T~SCM~ cells remain uninvestigated. The characterization of CD4 + T~SCM~ cells seems to be of great importance all the more, as the role of CD4 + T cells as broad orchestrators of the immune response receives growing attention in anti-tumour immunotherapy ([@bb0105], [@bb0130]). In the present study, therefore, focus was put on the induction and characterization of CD4 + T~SCM~ cells, nevertheless testing the relevance of our findings on T~SCM~ cell induction also for CD8 + T~SCM~ cells.

Here, we revealed the inhibition of mTORC1 with simultaneously active mTORC2 signalling as the molecular mechanism inducing T~SCM~ cells and that T~SCM~ cell induction takes place in complete independence from Wnt signalling. We furthermore present insights into the transcriptomes of naturally occurring and pharmacologically induced CD4 + T~SCM~ cells, the *in vivo* survival and repopulation capacity of pharmacologically induced CD4 + T~SCM~ cells and the metabolic regulation of CD4 + T~SCM~ cell generation. Taken together, our findings are of direct relevance for the design of improved anti-tumour immunotherapies.

2. Materials & Methods {#s0010}
======================

2.1. Human T Lymphocytes {#s0015}
------------------------

Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation over a Ficoll-Paque gradient (Lymphoprep™) from buffy coats of healthy human female and male blood donors, obtained from the Vaud blood transfusion service. Experiments were performed in accordance to the guidelines of the Ethics Commission of the UNIL. Prior to sorting, PBMCs were purified with CD3, CD4 or CD8 Dynabeads® (Invitrogen™).

2.2. Animal Experiments {#s0020}
-----------------------

Animal experiments were performed in accordance to the guidelines of the Ethics Commission of the UNIL. *In vitro* experiments and assessment of T~SCM~ cell frequencies were performed with female Raptor (CD4-Cre), β-/γ-catenin (Vav-Cre) KO mice and their corresponding WT forms. Adoptive T cell transfer was conducted with female NOD.Cg-Prkdc^scid^Il2rg^tm1WjI^/SzJ mice (NSG).

2.3. Cell Culture {#s0025}
-----------------

T cells were cultured in RPMI-1640 supplemented with 8% heat inactivated, pooled human serum or 10% foetal calf serum, 50 IU/ml penicillin, 50 μg/ml streptomycin, 4 mM [l]{.smallcaps}-glutamine, 1% (v/v) non-essential amino acids and 50 μM 2-mercaptoethanol. Sorted T~N~ cells were primed with anti-CD3/CD28 beads (Invitrogen) or OKT3/anti-CD28 antibody (in house, derived from hybridoma cells) and IL-2 (Proleukin®, Roche Pharma AG). Pathway interfering drugs were TWS119 (Cayman Chemical), rapamycin (LC Laboratories), PP242 (Chemdea), KU-0063794 (Chemdea), Indirubin-3-monoxime (Sigma-Aldrich), SB216763 (Sigma-Aldrich) and recombinant human Wnt3A (R&D Systems).

2.4. Flow Cytometry {#s0030}
-------------------

Flow cytometry acquisition was performed with a Gallios™ (Beckman Coulter) or a LSR II flow cytometer (BD Biosciences). Cell sorting was conducted with a FACS Aria (BD Biosciences) or a MoFlo® Astrios™ cell sorting instrument (Beckman Coulter). Flow cytometry analysis was performed with FlowJo software (Version 7.6.5, Treestar).

Antibodies and staining panels are listed in the *Supplemental Experimental Procedures*.

2.5. Phospho-specific Flow Cytometry {#s0035}
------------------------------------

1,000,000 T~N~ cells were sorted per condition. After activation with anti-CD3/CD28 beads (1:1 bead/cell ratio) in the presence of TWS119 (5 μM) or rapamycin (100 nM) for 4 h, T~N~ cells were harvested, fixed and incubated with ice-cold 50% methanol for membrane permeabilization. Primary antibodies were pS6 ribosomal protein (Ser235/236), pGSK-3β (Ser9), pAKT (Ser473), p4EBP1 (Ser65), p4EBP1 (Thr37/46) (all from Cell Signaling). The secondary antibody was Alexa Fluor 647 goat anti rabbit IgG (Life Technologies).

2.6. Western Blot Analysis {#s0040}
--------------------------

For Western blot analysis activated (4 h in presence of indicated drugs) natural (n) CD4 + T~N~ cells were washed in ice-cold PBS and lysed in RIPA buffer containing protease inhibitor and sodium orthovanadate (Santa Cruz Biotechnologies). Proteins were separated by 4% to 12% polyacrylamide gel and transferred to a polyvinylidene difluoride membrane (Millipore). Membranes were blocked with Odyssey® blocking buffer (LI-COR Biosciences) and immunoblotted with the primary antibodies pS6 ribosomal protein (Ser235/236), pAKT (Ser473), β-actin (all from Cell Signaling) followed by infrared secondary antibodies. Bands from immunoreactive proteins were visualized by an Odyssey® infrared imaging system (LI-COR Biosciences).

2.7. RNA Sequencing {#s0045}
-------------------

RNA sequencing was conducted with nCD4 + T~N~, T~SCM~ and T~CM~ cells from 4 healthy human donors. Additionally, TWS119- and rapamycin-induced T~SCM~ cells were resorted after 14 days of nCD4 + T~N~ cell priming from the same donors. RNA was purified with Arcturus PicoPure RNA Isolation kit (Biosystems/Applied Life Technologies). An amount of 10 ng total RNA was amplified with the SMARTer Ultra Low RNA Kit for Illumina Sequencing (Clontech Laboratories, Inc.) and the Advantage 2 PCR Kit (Clontech Laboratories, Inc.). The cDNA from the amplification reactions was sheared with a Covaris ultrasonicator (Covaris, Inc.) and sequencing libraries were generated with a Truseq DNA kit (Illumina, Inc.). Libraries were sequenced at 100 nucleotides single read mode on an Illumina HiSeq 2000 instrument.

2.8. Adoptive T Cell Transfer {#s0050}
-----------------------------

Adoptive T cell transfer was conducted by tail vein injection of 200,000 rapamycin-induced CD4 + T~SCM~ cells and equal numbers of CD4 + T~N~-like and T~CM~-like cells. Control mice received an equal volume of culture medium. Lymphocytes from lung and liver were isolated by Percoll™ technique.

2.9. Cell Proliferation Assay {#s0055}
-----------------------------

30,000 rapamycin-induced CD4 + T~SCM~ cells and equal numbers of T~N~- and T~CM~-like cells were labelled for 6 days with carboxyfluorescein succinimidyl ester (CFSE, Life Technologies) (final concentration: 0.25 μM) and expanded in presence of IL-2 (50 IU/ml). Dilution of CFSE (488 nm) was assessed by flow cytometry. The proliferation index was calculated with ModFit LT software (Version 3.3.11, Verity Software House, Inc.).

2.10. MMP {#s0060}
---------

Assessment of MMP was performed with TMRE --- Mitochondrial Membrane Potential Assay Kit (Abcam®). 5,000,000 nCD4 + T cells and equal numbers of T cells derived from nCD4 + T~N~ cells, which have been activated for 14 days in presence of rapamycin (100 nM), were used. T cells were incubated with 100 nM tetramethylrhodamine, ethyl ester (TMRE) for 30 min at 37 °C in the water bath. Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP, 100 μM) was added during acquisition.

2.11. 2-NBDG Uptake {#s0065}
-------------------

2-\[N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino\]-2-deoxy-[d]{.smallcaps}-glucose (2-NBDG, Invitrogen) uptake was carried out with 5,000,000 nCD4 + T cells and equal numbers of T cells, derived from nCD4 + T~N~ cells, which have been activated for 14 days in presence of rapamycin (100 nM). T cells were incubated for 15 min at 37 °C in glucose-free Krebs-Ringer Hepes buffer (Hepes 50 mM, NaCl 137 mM, KCl 4.7 mM, CaCl~2~ 1.85 mM, MgSO~4~ 1.3 mM, BSA 0.1% w/v, pH 7.4). T cells were pelleted, washed and incubated with 100 μM 2-NBDG at 37 °C in the water bath prior to measuring fluorescence by flow cytometry.

2.12. Assessment of ECAR and OCR {#s0070}
--------------------------------

For extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) measurements we used an XF24 extracellular analyser (Seahorse™ Bioscience). T~N~ (750,000 per well) and T~SCM~ cells (200,000 per well) have been immobilized using CellTak™ agent (BD Biosciences). T cells were kept in non-buffered assay medium (KHB with 25 mM glucose, 1 mM sodium pyruvate, 2 mM glutamine for ECAR assessment or 2.5 mM glucose and 1.5 mM carnitine for OCR measurement) and incubated in a non-CO~2~ incubator for 60 min at 37 °C prior to analysis. Anti-CD3/CD28 beads, TWS119, rapamycin, oligomycin and palmitate were added prior to or during the analysis at the indicated time points and concentrations. ECAR and OCR were calculated using Seahorse™ Bioscience proprietary software.

2.13. Statistical Analysis {#s0075}
--------------------------

### 2.13.1. Flow Cytometry {#s0080}

Statistical analysis was performed with Prism software (Version 6, GraphPad), using a paired t-test.

### 2.13.2. RNA Sequencing {#s0085}

The raw sequencing reads were trimmed with Trim Galore! (<http://www.bio-informatics.babra-ham.ac.uk/projects/trim_galore/>) (Version 0.3.3), using cutadapt (Version 1.2.1) to remove low-quality bases (quality Phred score cut-off 15) and remaining adaptor sequences. Further information is provided in the Supplemental Experimental Procedures. For all analyses, a p-value (adj.) less than 0.05 was considered as statistically significant and labelled with \*, less than 0.01 with \*\*, less than 0.001 with \*\*\* and less than 0.0001 with \*\*\*\*.

3. Results {#s0090}
==========

3.1. TWS119 and Rapamycin Induce Phenotypic T~SCM~ Cells {#s0095}
--------------------------------------------------------

To assess the influence of Wnt and mTOR on human T~SCM~ cell generation, highly purified CD4 + and CD8 + T~N~ cells (natural (n)) were sorted *ex vivo* (Fig. S1a) and activated with anti-CD3/CD28 beads (1:1 bead/cell ratio) and IL-2 (300 IU/ml) in the presence of the Wnt activator TWS119 (5 μM) or the mTOR inhibitor rapamycin (100 nM).

After 14 days, nCD4 + T~N~ cells, primed in the presence of TWS119 or rapamycin, formed two lymphocyte populations, a small-sized and a large-sized one, based on forward scatter/side scatter (FSC/SSC) profiles. In contrast, nCD4 + T~N~ cells which have been cultured in the absence of TWS119 or rapamycin did not generate the small-sized lymphocyte population ([Fig. 1](#f0005){ref-type="fig"}a). Phenotypic analysis revealed that the small-sized lymphocyte population mainly consists of T cells with a CCR7 +, CD45RA + T~N~-like phenotype and a small fraction of cells with a CCR7 +, CD45RA- T~CM~-like phenotype. Of note, the T~N~-like population displayed phenotypic CD95 +, CD58 + T~SCM~ cells which were significantly increased in absolute cell numbers in comparison to T~CM~-like cells ([Fig. 1](#f0005){ref-type="fig"}b, Fig. S1b and [Table 1](#t0005){ref-type="table"}), suggesting TWS119 and rapamycin as specific inducers of T~SCM~ cells. These cells co-expressed high levels of the CD62L selectin (not shown). We then subdivided the T~N~-like population into a CCR7 +, CD45RA^intermediate^ "transition zone" (TZ) and a CCR7 +, CD45RA^high^ "rand zone" (RZ) to investigate whether T~SCM~ cells would be preferentially located in a distinct region of the T~N~-like population. Interestingly, this was indeed the case, since the TZ contains higher frequencies of phenotypic T~SCM~ cells compared to the RZ ([Fig. 1](#f0005){ref-type="fig"}B), in line with a model of progressive T cell differentiation, positioning T~SCM~ cells in between T~N~ cells and T~CM~ cells. The large-sized lymphocyte population did not show significant differences in cellular composition upon drug treatment with or without TWS119 or rapamycin and exhibited a mixture of T~N~-like, T~CM~-like and T~EM~-like (CCR7 −, CD45RA −) cells (Table S1), suggesting the small-sized lymphocyte population as place of CD4 + T~SCM~ cell induction.

To further explore the mechanism of T~SCM~ cell induction by TWS119 and rapamycin, we next tested the alternative Wnt activators Indirubin-3-monoxime (4 μM) and Wnt3A (10 nM) as well as the ATP-competitive mTOR inhibitors PP242 and KU-0063794. PP242 and KU-0063794 used at low concentrations (100 nM) inhibit mTORC1, while at higher concentrations (1 μM) they also block mTORC2 (data not shown). Supporting our finding with rapamycin, 14 days of nCD4 + T~N~ cell priming in the presence of low-concentrations (100 nM) PP242 or KU-0063794 also triggered the formation of a small-sized lymphocyte population with phenotypic T~SCM~ cells ([Fig. 1](#f0005){ref-type="fig"}c and Fig. S1d). However, surprisingly in contrast to TWS119, the alternative Wnt activators Indirubin-3-monoxime and Wnt3A did not generate a small-sized lymphocyte population ([Fig. 1](#f0005){ref-type="fig"}c), questioning an involvement of Wnt signalling in T~SCM~ cell induction.

Testing these observations for CD8 + T~SCM~ cell induction, priming of highly purified nCD8 + T~N~ cells for 14 days in the presence of TWS119 or rapamycin, in comparison to drug absence or priming in the presence of Indirubin-3-monoxime (4 μM), resulted in increased frequencies of T~N~-like cells, displaying a population of phenotypic CD95 +, CD58 + T~SCM~ cells (Fig. S1c), suggesting a common pharmacological mechanism of rapamycin and TWS119 also for CD8 + T~SCM~ cell induction. Thus, taken together, inhibitors of mTOR induce phenotypic CD4 + and CD8 + T~SCM~ cells, whereas, apart from TWS119, other Wnt activating drugs fail in doing so.

3.2. TWS119 Inhibits mTORC1 {#s0100}
---------------------------

To test the hypothesis about a common pharmacological mechanism of TWS119 and rapamycin in T~SCM~ cell induction, the phosphorylation of GSK-3β (pGSK-3β, read-out for Wnt activity) and the phosphorylation of S6 ribosomal protein (pS6, read-out for mTORC1 activity) were assessed by flow cytometry in highly purified human nCD4 + T~N~ cells ([Fig. 2](#f0010){ref-type="fig"}a) and nCD8 + T~N~ cells ([Fig. 2](#f0010){ref-type="fig"}b) as well as by Western blot analysis for pS6 in highly purified human nCD4 + T~N~ cells ([Fig. 2](#f0010){ref-type="fig"}c) upon activation and drug interference.

Surprisingly, the Wnt activator TWS119, which was able to induce phenotypic T~SCM~ cells, also abolished the phosphorylation of S6 ([Fig. 2](#f0010){ref-type="fig"}a to c), suggesting an inhibitory effect of TWS119 on mTORC1. Interestingly, whereas the drugs which inhibited mTORC1 (decrease of S6 phosphorylation) were also capable to induce phenotypic T~SCM~ cells, the drugs which activated Wnt (increase of pGSK-3β) did not induce phenotypic T~SCM~ cells, suggesting that phenotypic T~SCM~ cell induction is mediated by inhibition of mTORC1. In line with reports on differential effects on S6 and 4EBP1 ([@bb0040]), TWS119 and rapamycin had no significant effects on p4EBP1, another protein downstream of mTORC1, in nCD4 + T~N~ cells (Fig. S2a) and nCD8 + T~N~ cells (Fig. S2b). Moreover, our results suggest that both TWS119 and rapamycin are exerting a mild, suboptimal effect on mTORC1 inhibition (S6K is blocked but 4EBP1 is preserved, as is also mTORC2). Previous studies have demonstrated that S6K is a more sensitive target of mTOR blockade than 4EBP1 ([@bb0045], [@bb0065]). Thus, inhibition of mTORC1 via decrease of S6 phosphorylation and independence from Wnt signalling emerge as the molecular mechanisms which underlie T~SCM~ cell induction.

3.3. TWS119 Induces a Differentiation Arrest Independently From Wnt Signalling {#s0105}
------------------------------------------------------------------------------

To confirm this conclusion on a genetic base, we took advantage of highly purified nCD4 + T~N~ cells from mice with a haematopoietic deletion of β- and γ-catenin, resulting in abolished Wnt signalling. In mice, T~SCM~ cells were phenotypically defined by the expression of Sca-1 (Ly6A/E) and CXC chemokine receptor 3 (CXCR3) on naive-appearing CD44 −, CD62L + T cells (Fig. S3a) ([@bb0085], [@bb0210]). Since mouse nCD4 + T~N~ cells did not tolerate long drug treatment phases, we needed to reduce priming periods to 4 days with 1.5 μM TWS119, an interval possibly too short to trigger an up-regulation of T~SCM~ cell markers. However, to confirm its independence from Wnt signalling, we hypothesised that under these conditions TWS119 would at least arrest a fraction of activated β- and γ-catenin KO nCD4 + T~N~ cells in a T~N~-like state, in analogy to the formation of the small-sized lymphocyte population observed in the *in vitro* experiments with human nCD4 + T~N~ cells. Interestingly, as observed for the mTORC1 inhibitor rapamycin, this was also indeed the case for TWS119, whereas the alternative Wnt activator SB216763 (2 μM), which does not inhibit mTORC1, failed in doing so ([Fig. 3](#f0015){ref-type="fig"} and [Fig. 2](#f0010){ref-type="fig"}c). Thus, these data further confirm that the mediation of a differentiation arrest, as prerequisite for T~SCM~ cell induction, is independent from Wnt signalling, but dependent on mTORC1 inhibition. To further corroborate these findings, we then assessed T~SCM~ cell levels in the spleens of β- and γ-catenin KO mice, using the above mentioned phenotype. Suggesting no impairment in T~SCM~ cell generation in the absence of Wnt signalling, β- and γ-catenin KO mice exhibited naturally occurring T~SCM~ cells in comparable frequencies as their WT counterparts (Fig. S3b). Furthermore, we took advantage of mice with a T cell-specific KO of the mTORC1 regulatory component Raptor, which leads to an abolishment of mTORC1 signalling. Interestingly, supporting our *in vitro* findings of rapamycin-mediated T~SCM~ cell induction, we found significantly increased T~SCM~ cell frequencies in these mice (Fig. S3c and Fig. S3d). Moreover, excluding an off-target effect of rapamycin, additional treatment of Raptor KO nCD4 + T~N~ cells during 4-day priming with rapamycin (100 nM) did not result in an increased fraction of cells in a T~N~-like state (Fig. S3e). Altogether, these data present further evidence for the inhibition of mTORC1 as the molecular mechanism underlying T~SCM~ cell induction.

3.4. Transcriptome Analysis of Naturally Occurring and Pharmacologically Induced T~SCM~ Cells {#s0110}
---------------------------------------------------------------------------------------------

By transcriptome analysis, we next set out to assess the degree of relatedness between naturally occurring CD4 + T~N~, T~SCM~ and T~CM~ cells as well as TWS119- and rapamycin-induced CD4 + T~SCM~ cells to gain insights into distinct profiles of gene expression in CD4 + T~SCM~ cells. In naturally occurring T cell subsets, unsupervised analysis showed a very close relatedness between T~SCM~ and T~CM~ cells compared to T~N~ cells ([Fig. 4](#f0020){ref-type="fig"}a and b), potentially indicating a continuous transition from T~SCM~ to T~CM~ cells during differentiation. Suggesting CD4 + T cell differentiation as process which may be strictly regulated by a core set of genes, only 895 genes were found to be significantly differentially expressed between T~N~ and T~SCM~ cells and 141 genes between T~SCM~ and T~CM~ cells by supervised analysis (adj. p \< 0.05; \| log2FC \| \> 1) ([Fig. 4](#f0020){ref-type="fig"}c, Table S2, Table S3). To identify further differences between T~SCM~ and T~CM~ cells with respect to the stem cell-like nature of T~SCM~ cells, we carried out a gene set enrichment analysis for stem cell characteristic genes (view Supplemental Information) and could identify *FGFR1*, *RB1* and *NOTCH2* to be highly expressed in T~SCM~ cells in comparison to T~CM~ cells (adj. p = 0.07). Of further interest for the distinction of T~SCM~ from T~CM~ cells, 18 genes were found to be significantly differentially expressed between these otherwise closely related subsets and not shared by any other subset ([Fig. 4](#f0020){ref-type="fig"}c and Table 4). In addition, a set of 56 genes could be identified to be significantly differentially expressed between T~N~ and T~SCM~ cells and between T~SCM~ and T~CM~ cells, thus, showing a unique expression profile in T~SCM~ cells ([Fig. 4](#f0020){ref-type="fig"}c and [Table 2](#t0010){ref-type="table"}). Interestingly, from these 56 genes only 4 genes, *SLC22A17*, *RAI2*, *SALL2* and *LOC338651*, were down-regulated in T~SCM~ cells (Fig. S4a), whereas all the other genes were up-regulated. Moreover, with exception of *TCF4*, Wnt signalling transducers could be found to be highly expressed either in both, T~N~ and T~SCM~, or significantly up-regulated in T~N~ cells, further arguing against the theory that activation of the Wnt pathway in T~N~ cells induces T~SCM~ cells (Fig. S4b).

Interestingly, TWS119- and rapamycin-induced T~SCM~ cells showed a very close degree of relatedness. From 21,481 interrogated genes, only 565 genes were significantly differentially expressed between them (adj. p \< 0.05; \| log2FC \| \> 1), further supporting our finding of a common pharmacological mechanism of these drugs ([Fig. 4](#f0020){ref-type="fig"}a to c and Table S5). However, since TWS119- and rapamycin-induced T~SCM~ cells have received strong activating stimuli over 14 days, it was likely that their transcriptome differed from the ones of naturally occurring T~SCM~ cells, directly sorted *ex vivo* in their resting state. Nonetheless, we hypothesised that the set of well-known factors of human effector and memory T cell differentiation would show a comparable expression profile in naturally occurring and pharmacologically induced T~SCM~ cells ([@bb0090]). Indeed, similar expression levels of the regulators of effector differentiation *CXCR3*, *KLRG1*, *PRDM1* and *TBX21* could be found ([Fig. 4](#f0020){ref-type="fig"}d). Interestingly, *in vitro* induced T~SCM~ cells exhibited higher expression levels of *GZMA* and *PRF1* ([Fig. 4](#f0020){ref-type="fig"}d), probably equipping them with superior direct effector functions. *In vitro* induced and naturally occurring T~SCM~ cells displayed a similar expression level of *TNF*, but, notably, *in vitro* induced T~SCM~ cells exhibited low *IFNG* expression levels (Fig. S4c). This might be a result of *IFNG* down-regulation due to mTORC1 inhibition, a mechanism described for type I interferons in plasmacytoid dendritic cells mediated by interferon-regulatory factor (IRF) 7 ([@bb0025]). Interestingly, IRFs are involved in CD4 + T cell differentiation ([@bb0115]), and *IRF7* was found to be up-regulated in *in vitro* induced T~SCM~ cells (Fig. S4c). Furthermore, similar expression levels of the inhibitory factors for T cell activation and differentiation *CERS6*, *EOMES*, *LEF1*, *TAF4B* and *ACTN1* as well as for the T~SCM~ cell characteristic factors *CD27*, *ITGAL*, *IL2RB* and *TNFSF9* could be identified ([Fig. 4](#f0020){ref-type="fig"}d). In addition, the expression levels of genes encoding distinct interleukins are shown in Fig. S4d. Finally, confirming the purity of the performed cell sorts, naturally occurring T~N~, T~SCM~ and *in vitro* induced T~SCM~ cells expressed similarly low amounts of *HNRPLL*, a key regulator of the alternative splicing of the *CD45* pre-mRNA ([@bb0135]). Additionally, *FAS* was among the most significantly differentially expressed genes between naturally occurring T~N~ and T~SCM~ cells (Fig. S4e). Altogether, these data present insights into the transcriptional regulation of T~SCM~ cells and underline the pharmacological inhibition of mTORC1 as a molecular mechanism to confer stemness to a population of activated T~N~ cells.

3.5. *In Vitro* Induced T~SCM~ Cells Exhibit a Long-term Repopulation Capacity *in Vivo* {#s0115}
----------------------------------------------------------------------------------------

The distinct up-regulation of transcripts encoding telomerase, anti-apoptotic genes and positive cell cycle regulators and down-regulation of pro-apoptotic genes and CDK inhibitors (Fig. S5a) ([@bb0100], [@bb0190]) suggested that *in vitro* induced CD4 + T~SCM~ cells might exhibit a superior *in vivo* long-term persistence. We directly assessed this potential *in vivo* long-term persistence by adoptive transfer of 200,000 rapamycin-induced CD4 + T~SCM~ cells, isolated to high purity by flow cytometry-based cell sorting, into NOD.Cg-Prkdc^scid^Il2rg^tm1Wjl^/SzJ (NSG) mice. Ten weeks after adoptive transfer, peripheral blood, spleen, bone marrow, lung and liver were investigated by multicolour flow cytometry for T~SCM~ cell persistence ([Fig. 5](#f0025){ref-type="fig"}a and Fig. S5b). Interestingly, in two of three experiments, the spleens of the mice, which have received T~SCM~ cells, showed the presence of a live CD3 +, CD4 + T cell population with a CCR7 −, CD45RA^intermediate^ phenotype ([Fig. 5](#f0025){ref-type="fig"}a), indicating both, the potential of *in vitro* induced CD4 + T~SCM~ cells to persist long-term *in vivo* and their ability to repopulate the effector pools by giving rise to further differentiated progeny. In a third experiment, adoptively transferred T~SCM~ cells yielded live CD3 +, CD4 + T cells in the peripheral blood ten weeks after adoptive transfer ([Fig. 5](#f0025){ref-type="fig"}a). In contrast, no T cells could be detected after adoptive transfer of same numbers of T~N~-like or T~CM~-like cells, re-sorted from the small-sized lymphocyte population from the same *in vitro* cell culture (Fig. S5b). Spleen size and weight did not exhibit any differences between the groups (Fig. S5b). Of note, compared to naturally occurring CD4 + T~N~ cells, *in vitro* induced CD4 + T~SCM~ cells showed an up-regulation of the haematopoietic stem cell engraftment genes *HOXA1* and *LPXN* ([@bb0145]), which might have mediated their superior engraftment capacity (Fig. S5c). Together, these data suggest a potential advantage of pharmacologically induced CD4 + T~SCM~ cells in mediating a prolonged immune response after adoptive transfer. Of note, we did not observe signs of xeno-GVHD in contrast to a report showing that rapamycin-treated T cells caused more xeno-GVHD ([@bb0005]). Further studies are warranted to assess the relative functional features of rapamycin-induced T~SCM~ cells and their long-term repopulation capacity after adoptive transfer.

Next, the proliferative capacity of 30,000 rapamycin-induced CD4 + T~SCM~ cells in comparison to equal numbers of T~N~-like and T~CM~-like cells, re-sorted from the small-sized lymphocyte population from the same *in vitro* cell culture, was assessed by CFSE dilution assay. T cells were either left for 6 days in presence of IL-2 (50 IU/ml) or, additionally, stimulated with OKT3 (1 μg/ml) and anti-CD28 antibody (10 μg/ml) ([Fig. 5](#f0025){ref-type="fig"}b). Interestingly, in two of six experiments, stimulated *in vitro* induced T~SCM~ cells formed a small-sized resting T cell population in addition to a large proliferating one, probably reflecting their stem cell nature, which is both, the capacity to self-renew and to differentiate ([Fig. 5](#f0025){ref-type="fig"}b).

3.6. Substrate Utilization and Cellular Metabolism of T~SCM~ Cells {#s0120}
------------------------------------------------------------------

Increasing evidence suggests that T cell differentiation is controlled by fine-tuned modulations of glycolysis and fatty acid oxidation (FAO) ([@bb0030], [@bb0080], [@bb0215]). To investigate the predominance of a distinct metabolic programme in T~SCM~ cells, we next measured the uptake capacity of the fluorescent glucose analogue 2-NBDG in rapamycin-induced T~SCM~ cells in comparison to T~N~-like, T~CM~-like and T~EM~-like cells and to the respective naturally occurring T cell subsets as reference point for glycolytic activity ([@bb0170]). Interestingly, compared to the divergent glucose uptake of T~EM~ cells and T~EM~-like cells, all other T cell subsets exhibited a limited glucose uptake, suggesting especially for T~SCM~ cells an independence from glycolysis ([Fig. 5](#f0025){ref-type="fig"}c). In line, pharmacologically induced T~SCM~ cells also showed low expression of the gene encoding the master regulator of glycolytic enzyme *HIFA* (Fig. S5d). Alternatively, as reference point for oxidative metabolism such as FAO, we measured the mitochondrial membrane potential (MMP) in the mentioned T cell subsets by assessment of their uptake of TMRE, a dye, which accumulates in active mitochondria of short-lived effectors ([@bb0165]). Accordingly, we could find an increase of TMRE uptake going along with progressive cellular differentiation ([Fig. 5](#f0025){ref-type="fig"}d).

Since these observations suggest that T~SCM~ cells rather gain their energy from an oxidative metabolism, we hypothesised that FAO might also be the relevant metabolic programme in the induction of T~SCM~ cells. We, therefore, investigated the impact of the pharmacological T~SCM~ cell inducers TWS119 and rapamycin on the metabolism of activated nCD4 + T~N~ cells by assessment of ECAR, which is an indicator of glycolytic activity, and OCR, which is an indicator of mitochondrial respiration, by Seahorse analysis ([Fig. 5](#f0025){ref-type="fig"}e left). Interestingly, administration of TWS119 (5 μM) or rapamycin (100 nM) prevented the development of full cellular glycolytic activity in response to oligomycin (1 μg/ml), a drug, enforcing maximal glycolysis. Thus, we hypothesised that TWS119 and rapamycin initiate a metabolic programme for T~SCM~ cell induction which is alternative to glycolysis. To disclose whether this metabolic programme would be FAO, we triggered mitochondrial respiration in rapamycin-pretreated (100 nM, 2 h) and activated nCD4 + T~N~ cells by administration of palmitate (500 μM), the ester of retinol and palmitic acid. Interestingly, the presence of palmitate increased mitochondrial respiration to the levels measured in nCD4 + T~SCM~ cells ([Fig. 5](#f0025){ref-type="fig"}e right). Thus, these data present evidence for FAO as metabolic programme characteristic of T~SCM~ cells and needed for T~SCM~ cell induction.

4. Discussion {#s0125}
=============

The identification of the signalling pathways, underlying T~SCM~ cell formation, allows their targeted induction and paves the way for the design of novel immunotherapeutic approaches. Here, we show the emergence of a T cell population with phenotypic, transcriptional, functional and metabolic hallmarks of naturally occurring T~SCM~ cells upon *in vitro* inhibition of mTORC1 during priming of human T~N~ cells. These findings emphasize the potential relevance of the signalling network of mTOR kinase in immunotherapy and of mTOR modulating pharmacological agents.

Interestingly, we show that mTORC1 inhibition with drugs like rapamycin mediates an immunostimulatory effect by the induction of T~SCM~ cells, although these drugs are generally used because of their immunosuppressive function ([@bb0050], [@bb0075]). Thus, these observations indicate that there are distinct conditions which trigger either a preferential immunostimulatory or an immunosuppressive rapamycin effect. Among a variety of different molecular mechanisms, rapamycin has been suggested to fulfil its immunosuppressive function by prevention of full T cell activation ([@bb0110], [@bb0175]). This effect can be circumvented by strong stimulation of the TCR and co-stimulatory receptors ([@bb0160]). Similarly, in the *in vitro* experiments the high degree of activation of T~N~ cells by anti-CD3/CD28 beads in a 1:1 bead/cell ratio and 300 IU/ml IL-2 might have favoured an immunostimulatory rapamycin effect. Furthermore, rapamycin has been shown to increase the antigen-specific T cell response to a pathogen (short-term persistence of the antigen), but to fail in doing so in response to a graft (long-term persistence of the antigen) ([@bb0070]). These findings strongly suggest that the period of antigen persistence also regulates the immunological outcome of rapamycin. Thus, the rather short periods of T~N~ cell activation (14 days and 4 days) in our *in vitro* experiments might have tipped the balance towards an immunostimulatory rapamycin effect. The used concentration of rapamycin also emerges as an important factor for mediating either an immunostimulatory or an immunosuppressive drug effect. For the *in vitro* induction of T~SCM~ cells, rapamycin was used in 100 nM (90 ng/ml), since a rather high concentration of 40--100 ng/ml rapamycin, administered during the contraction phase, has been shown to qualitatively improve antigen-specific memory T cells in a mouse model of CD8 + T cell response to acute viral infection ([@bb0010]). In contrast, 8--12 ng/ml rapamycin blood levels are intended to induce immunosuppression after transplantation ([@bb0015]). Together, this suggests that a low rapamycin concentration preferentially results in an immunosuppressive effect, whereas a high rapamycin concentration triggers an immunostimulatory one. Also the immunomodulatory actions of rapamycin might be regulated by the interplay between the two mTOR complexes. Whereas T~SCM~ cell induction, as shown here, follows mTORC1 inhibition without additional inhibition of mTORC2, formation of immunosuppressive regulatory T cells is favoured in additional absence of mTORC2 signalling ([@bb0035]). Thus, immunomodulation by rapamycin appears to be a fine-tuned, highly multidimensional process.

Furthermore, we show that the induction of T~SCM~ cells is completely independent from the Wnt signalling pathway. In line with this, the role of Wnt in memory T cell formation has already been called into question by reports about memory T cell formation in CD8 + T cells, in which β-catenin was conditionally knocked out ([@bb0060], [@bb0150]). Nevertheless, these reports have to be seen with caution, since, in contrast to our study, specifically, T~SCM~ cell formation was not investigated and mice with KO of only β-catenin, which might have favoured a bypassed activity of Wnt signalling by γ-catenin, were used. Moreover, our data offer an unexpected answer to the paradox finding that the Wnt activator TWS119 induces T~SCM~ cells, whereas none of alternative Wnt activators was able to do so, by the discovery of an mTORC1 inhibiting effect of TWS119. Interestingly, this effect finds further confirmation by a recent report, confirming in mouse T cells that TWS119 inhibits mTORC1 ([@bb0200]). At present, it is unclear what the scope of TWS119 off-target effects on other kinases is or whether its inhibition of the mTORC1 kinase requires, as rapamycin, FKBP12. Future biochemical and pharmacological studies will have to address the precise molecular mechanism of mTORC1 inhibition by TWS119.

We also showed that mTORC1 inhibition switched the metabolic programme of activated nCD4 + T~N~ cells to an oxidative metabolism dependent on FAO. However, prominently, in the *in vitro* experiments only a fraction of activated T~N~ cells was arrested in a T~N~-like state by TWS119 or rapamycin, suggesting that not all T~N~ cells from the phenotypically homogenous CCR7 +, CD45RA + starting population react to mTORC1 inhibition in the same way. Future studies will have to address whether T~N~ cell intrinsic factors can be identified which predispose certain cells to stop differentiation upon mTORC1 inhibition. One such factor might be Krüppel-like-factor 2 (KLF2) which has been shown to maintain the expression of CCR7 and CD62L and has been suggested to be up-regulated upon mTORC1 inhibition ([@bb0035], [@bb0185]). Interestingly, only a small fraction of the CCR7 +, CD45RA +, nCD4 + T~N~ cell starting pool exhibited a high KLF2 expression, whereas the vast majority showed a low expression of KLF2 (Fig. S5e), suggesting KLF2 as possible discriminator to delineate T~N~ cells with T~SCM~ cell precursor potential.

We sought to compare the transcriptome of CD4 + T~SCM~ cells induced by either TWS119 or rapamycin. Indeed, we observed a very highly overlapping gene expression signature shared by rapamycin- and TWS119-induced CD4 + T~SCM~ cells. Among 21,481 interrogated genes, only 565 genes were significantly differentially expressed between them (adj. p \< 0.05; \| log2FC \| \> 1), further supporting a common pharmacological mechanism of these drugs. It is very interesting that several of the up-regulated genes in the rapamycin treatment group were related with cell metabolism (Supplemental Table 5). Of note, the most highly up-regulated gene with rapamycin induction is NAD(P)H:quinone oxidoreductase (NQO1), which protects cells against oxidative stress and toxic quinones. In line with this, TXNRD1 (encoding the thioredoxin reductase 1) was also up-regulated in rapamycin-induced T~SCM~ cells. This protein could reduce thioredoxins and plays an important role in protection against oxidative stress. High expression of NQO1 and TXNRD1 might be closely related with the increased oxidative phosphorylation and fatty acid oxidation upon rapamycin induction of T~SCM~, which definitely needs to be addressed further. On the other hand, the most up-regulated gene in TWS119-induced T~SCM~ cells is LAMP3 (CD63). CD63 is barely expressed in naïve T cells but induced upon T cell activation. Crosslinking of CD63 has been shown to deliver a potent co-stimulatory signal to T cells. To our surprise, we noticed a striking induction of interferon responsive gene expression pattern in TWS119-induced T~SCM~ cells (for example, interferon-induced protein with tetratricopeptide repeats 2, IFIT2; Interferon-Induced Protein with Tetratricopeptide Repeats 3, IFIT3; interferon alpha-inducible proteins 6, IFI6; interferon alpha-inducible proteins 27, IFI27). Many of these genes have been shown to be important for antiviral innate immunity. Some of them emerge to play important roles in regulating T cell activation and immune response. For instance, ISG15 protease UBP43 (USP18) regulates T cell activation. USP18 deficient T cells exhibit hyperactivation of NF-κB and NFAT upon TCR triggering and are defective in Th17 differentiation. The roles of many of those genes in regulating T cells immunity remain to be determined in the near future.

From a translational standpoint, T~SCM~ cells emerge as most promising population for immunotherapy. In this regard, recent reports which indicate that the efficacy of CAR T cells might be based on their acquisition of a T~SCM~ cell phenotype are highly encouraging ([@bb0205]); however, previous work showed that also other T cell populations have the capacity to persist long-term *in vivo* ([@bb0020], [@bb0125]). Our data suggest the use of rapamycin for efficient *in vitro* T~SCM~ cell induction or *in vivo* application to enrich for antigen-specific T~SCM~ cells, which should be performed over a short period and by high drug concentration. However, the latter approach will need clinical studies titrating rapamycin doses and assessing different application time-points. Also our insights into T~SCM~ cell metabolism could be used for clinical purposes, since it seems to be rational to provide glucose in treatment phases in which a strong immune attack by T~EFF~ cells is desired. In contrast, in periods of long-term tumour control, in which T cells should enter low differentiation states, substrates allowing FAO should be unrestrictedly provided. In addition, future studies will have to assess the characteristics of and interplay between naturally occurring CD8 + T~SCM~ cells and CD4 + T~SCM~ cells as well as their rapamycin- and TWS119-induced counterparts in preclinical and clinical *in vivo* settings.

Thus, cellular signalling and metabolism emerge as most promising targets to influence T~SCM~ cell differentiation for the design of innovative immunotherapies.
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![TWS119 and rapamycin induce phenotypic T~SCM~ cells. (a) Highly purified (T~SCM~ cell-freed) human nCD4 + T~N~ cells activated for 14 days in the presence of TWS119 (5 μM) or rapamycin (100 nM) form a small-sized lymphocyte population which is not induced in the absence of TWS119 or rapamycin (red arrows). n = 5. (b) The small-sized lymphocyte populations induced by TWS119 or rapamycin mainly consist of CCR7 +, CD45RA + T~N~-like cells (gated on live CD3 +, CD4 + T cells) and exhibit a fraction of phenotypic CD95 +, CD58 + T~SCM~ cells with highest frequencies in the transition zone (TZ). The flow cytometry plot shows phenotypic T~SCM~ cells in the total T~N~-like cell population. T~SCM~ cell frequencies are depicted as percentages of the defined zones. Data are represented as mean ± SEM. FSC = forward scatter. SSC = side scatter. RZ = rand zone. T~SCM~ = pharmacologically induced phenotypic T~SCM~ cells. n = 5. (c) Activation of highly purified human nCD4 + T~N~ cells for 14 days in the presence of PP242 (100 nM) or KU-0063794 (100 nM) also leads to the formation of the small-sized lymphocyte population (red arrows), containing phenotypic CD95 +, CD58 + T~SCM~ cells (shown in the total T~N~-like cell population). In contrast, priming in the presence of the alternative Wnt activators Indirubin-3-monoxime (I-3-M, 4 μM) or Wnt3A (10 nM) does not lead to the formation of the small-sized lymphocyte population (red arrows). n = 4. T~SCM~ = pharmacologically induced phenotypic T~SCM~ cells.](gr1){#f0005}

![TWS119 inhibits mTORC1. Assessment of phosphorylation of GSK-3β (Ser9) and of phosphorylation of S6 ribosomal protein (Ser235/236) by flow cytometry in (a) highly purified (T~SCM~ cell-freed) nCD4 + T~N~ cells and in (b) highly purified nCD8 + T~N~ cells. n = 3. (c) Assessment of phosphorylation of S6 ribosomal protein (Ser235/236) by Western blot technique in highly purified nCD4 + T~N~ cells. n = 3. Activation of T~N~ cells in the presence of rapamycin (100 nM), PP242 (100 nM) and, of note, also of the Wnt activator TWS119 (5 μM) inhibits mTORC1 signalling. In contrast, the alternative Wnt activators Indirubin-3-monoxime (I-3-M, 4 μM), Wnt3A (10 nM) and SB216763 (4 μM) do not reduce phosphorylation of S6. NPA = no primary antibody. Beads = Anti-CD3/CD28 beads. TWS = TWS119. RAPA = rapamycin. MFI = median fluorescence intensity.](gr2){#f0010}

![TWS119 acts independently from Wnt. Both, TWS119 (1.5 μM) and rapamycin (100 nM), arrest a fraction of highly purified (T~SCM~ cell-freed) wild-type (WT, β-catenin^lox/lox^ γ-catenin^lox/lox^, top) and β- and γ-catenin knockout (KO, β-catenin^lox/lox^ γ-catenin^lox/lox^vav-cre, bottom) nCD4 + T~N~ cells after 4 days of *in vitro* activation with anti-CD3 (2 μg/ml), anti-CD28 antibody (2 μg/ml) and IL-2 (10 ng/ml). In contrast, SB216763 (2 μM) fails to mediate this differentiation arrest in activated WT and KO nCD4 + T~N~ cells. T~N~-like cell frequencies are depicted as percentages of live CD3 +, CD4 + T cells. n = 3. Data are represented as mean ± SEM. ns = not significant.](gr3){#f0015}

![Fate-determining key factors in naturally occurring and pharmacologically induced T~SCM~ cells. Heat map of gene expression among nCD4 + T~N~ cells, T~SCM~ cells and T~CM~ cells as well as TWS119- and rapamycin-induced CD4 + T~SCM~ cells. For interpretability, only the 1000 genes with the highest average normalized count levels across all samples were included in the heat map (Table S6). (b) Principal component analysis led to grouping of naturally occurring T cells on the one side and pharmacologically induced T cells on the other side by the first two principal components. In the first group, T~SCM~ cells and T~CM~ cells are most similar to each other. The first principle component captured a large fraction (35.5%) of the total variance in the data. (c) Venn diagram depicting overlaps among significantly differentially expressed genes found in pairwise comparisons between T~N~ cells, T~SCM~ cells and T~CM~ cells. Numbers indicate genes. The set of 56 genes is circled in red. (d) Comparative graphic representation of expression levels of naive/memory- and effector-associated genes in T~N~ cells, T~SCM~ cells, T~CM~ cells and TWS119- and rapamycin-induced T~SCM~ cells. The y-axes show normalized counts. Data are based on transcriptome analysis in 4 healthy human individuals. D1--4 = Donor 1--4. T~N~ = T~N~ cells. T~SCM~ = T~SCM~ cells. T~CM~ = T~CM~ cells. TWS = TWS119-induced T~SCM~ cells. RAPA = rapamycin-induced T~SCM~ cells.](gr4){#f0020}

![*In vivo* long-term repopulation capacity and cellular metabolism of CD4 + T~SCM~ cells. (a) Live CD3 +, CD4 + T cells with a CCR7 −, CD45RA intermediate phenotype can be detected in the spleen and peripheral blood of NSG mice, ten weeks after adoptive transfer of 200,000 rapamycin-induced CD4 + T~SCM~ cells. Con = control: injection of 200 μl culture medium. The grey underlay shows the distribution of CCR7 and CD45RA expression in live CD3 +, CD4 + T cells in a healthy donor control. n = 3. (b) Rapamycin-induced CD4 + T~SCM~ cells show a proliferative profile similar to the one of T~CM~-like cells. In two of six experiments, activated rapamycin-induced CD4 + T~SCM~ cells formed an additional small-sized lymphocyte population, which resisted to activating stimuli (red arrow). n = 6. (c) CD4 + T~EM~ and T~EM~-like cells display a divergent glucose uptake capacity. In comparison, nCD4 + T~N~, T~SCM~ and T~CM~ cells as well as rapamycin-induced CD4 + T~SCM~, T~N~-like and T~CM~-like cells do not show high 2-NBDG incorporation. n = 3. (d) Increase of mitochondrial membrane potential (MMP), measured by TMRE uptake, goes along with progressive T cell differentiation. Administration of the oxidative decoupler FCCP leads to immediate MMP breakdown, proving the T cells\` viability. n = 3. (e) Top: Activation of nCD4 + T~N~ cells with anti-CD3/CD28 beads increases ECAR (1). Administration of TWS119 (5 μM) or rapamycin (100 nM) (2) hinders activated T~N~ cells to fully develop glycolytic activity upon oligomycin (1 μg/ml) injection (3). n = 4. Bottom: Palmitate (500 μM) substitution increases the OCR in rapamycin-pre-treated, activated T~N~ cells to similar levels as the ones of nCD4 + T~SCM~ cells. n = 3. Data are represented as mean ± SEM. ECAR = extracellular acidification rate. OCR = oxygen consumption rate. AUC = area under the curve. T~N~ = T~N~ cells. T~SCM~ = T~SCM~ cells. T~CM~ = T~CM~ cells. T~EM~ = T~EM~ cells. T~N~-like = T~N~-like cells. T~CM~-like = T~CM~-like cells. T~SCM~ RAPA = rapamycin-induced T~SCM~ cells. RAPA = rapamycin. TWS = TWS119. BEADS = anti-CD3/CD28 beads.](gr5){#f0025}

###### 

Relative percentages and absolute cell numbers of live CD4 + T~N~, T~SCM~ and T~CM~ cells in the small-sized lymphocyte population. Numbers are presented as mean ± standard error of the mean (SEM). n = 5.

           Rapamycin      TWS119                             
  -------- -------------- ------------------ --------------- ------------------
  T~N~     86.37 ± 1.02   181.429 ± 19.055   72.36 ± 10.71   120.956 ± 22.647
  T~SCM~   7.97 ± 0.89    16.434 ± 2.175     11.79 ± 2.03    18.312 ± 1.827
  T~CM~    2.54 ± 0.48    5.215 ± 967        5.23 ± 2.46     7.741 ± 3.287

###### 

56 genes shared between the sets of genes found to be differentially expressed between the nCD4 + T~N~ cell and nCD4 + T~SCM~ cell groups as well as between the nCD4 + T~SCM~ cell and nCD4 + T~CM~ cell groups, but not between the nCD4 + T~N~ cell and nCD4 + T~CM~ cell groups.

  Gene name
  -------------------
  1\. IKZF4
  2\. SWAP70
  3\. FAM49A
  4\. HLA-DPB1
  5\. COBLL1
  6\. FCRL1
  7\. FCER1G
  8\. HBA1
  9\. SELP
  10\. HLA-DMB
  11\. CCL4
  12\. IFI30
  13\. IGLL5
  14\. BTK
  15\. LAYN
  16\. HLA-DMA
  17\. PTPN3
  18\. NKG7
  19\. WDFY4
  20\. PHACTR1
  21\. ANKRD33B
  22\. CDK14
  23\. COL19A1
  24\. CCL3
  25\. FAM129C
  26\. TLR5
  27\. SERPINA1
  28\. GFOD1
  29\. ARHGAP24
  30\. BANK1
  31\. ADAM12
  32\. GZMB
  33\. ARAP3
  34\. SLC22A17
  35\. IGJ
  36\. RAI2
  37\. TYROBP
  38\. PRF1
  39\. CAV1
  40\. FHL3
  41\. CNR2
  42\. LOC100130357
  43\. SALL2
  44\. KIAA0226L
  45\. CYBB
  46\. CD22
  47\. MNDA
  48\. MT1L
  49\. ALAS2
  50\. LYN
  51\. FCRL2
  52\. MS4A1
  53\. LOC338651
  54\. SNCA
  55\. SETBP1
  56\. HBG2
